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Abstract
We have examined whether Ad.sTbRFc and TAd.sTbRFc, two oncolytic viruses expressing soluble transforming
growth factor-b receptor II fused with human Fc (sTGFbRIIFc), can be developed to treat bone metastasis of
prostate cancer. Incubation of PC-3 and DU-145 prostate tumor cells with Ad.sTbRFc and TAd.sTbRFc produced
sTGFbRIIFc and viral replication; sTGFbRIIFc caused inhibition of TGF-b-mediated SMAD2 and SMAD3
phosphorylation. Ad(E1-).sTbRFc, an E1– adenovirus, produced sTGFbRIIFc but failed to replicate in tumor
cells. To examine the antitumor response of adenoviral vectors, PC-3-luc cells were injected into the left heart
ventricle of nude mice. On day 9, mice were subjected to whole-body bioluminescence imaging (BLI). Mice
bearing hind-limb tumors were administered viral vectors via the tail vein on days 10, 13, and 17 (2.5 · 1010 viral
particles per injection per mouse, each injection in a 0.1-ml volume), and subjected to BLI and X-ray radiography
weekly until day 53. Ad.sTbRFc, TAd.sTbRFc, and Ad(E1-).sTbRFc caused significant inhibition of tumor
growth; however, Ad.sTbRFc was the most effective among all the vectors. Only Ad.sTbRFc and TAd.sTbRFc
inhibited tumor-induced hypercalcemia. Histomorphometric and synchrotron micro-computed tomographic
analysis of isolated bones indicated that Ad.sTbRFc induced significant reduction in tumor burden, osteoclast
number, and trabecular and cortical bone destruction. These studies suggest that Ad.sTbRFc and TAd.sTbRFc
can be developed as potential new therapies for prostate cancer bone metastasis.
Introduction
Prostate cancer is the second leading cause of cancer-related deaths among men. During the advanced stages
of prostate cancer, a majority of the patients develop bone
metastases that result in severe bone pain, bone fractures,
and spinal cord compression, causing significant morbidity
and mortality (Bubendorf et al., 2000; Coleman, 2001). During
the late stages of cancer, tumors often become resistant to
conventional therapies including anti-androgen therapy
(McLeod, 2003; Damber and Aus, 2008; Harris et al., 2009;
Cannata et al., 2011; Sturge et al., 2011). Two types of therapies
available for targeting bone metastases are bisphosphonates
(such as zoledronic acid), and the now-approved denosumab,
an antibody against receptor activator of nuclear factor-jB
ligand (RANKL) (Coleman, 2011; Fizazi et al., 2011; Smith
et al., 2011; Sturge et al., 2011). Both these drugs are effective
in reducing bone resorption and skeleton-related events
(Coleman, 2011; Fizazi et al., 2011; Smith et al., 2011), but their
capacity to cure established bone metastases remains unclear.
Toward that end, there is a significant interest in developing
new drugs that would directly kill the tumor cells, and
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simultaneously target the surrounding microenvironment
that supports bone metastasis (Cooper et al., 2003; Loberg
et al., 2005; Coleman et al., 2010; Guise, 2010).
Transforming growth factor (TGF-b) has been shown to play
an important role in controlling bone metastasis of prostate
cancer (Massague, 2008; Sato et al., 2008; Nguyen et al., 2009;
Juarez and Guise, 2011). Prostate tumor cells are known to
produce TGF-b1 (Barrett et al., 2006), and high levels of TGF-b1
in the blood circulation, and TGF-b-dependent SMAD phos-
phorylation pathways in the tumors are poor prognostic
markers of prostate cancer (Shariat et al., 2001; Lu et al., 2007;
Schroten et al., 2011). Therefore, targeting TGF-b is an attractive
approach for the treatment of bone metastases (Iyer et al., 2005;
Massague, 2008; Sato et al., 2008; Jones et al., 2009; Nguyen et al.,
2009; Juarez and Guise, 2011; Mishra et al., 2011). Considering
these, and other studies that suggest oncolytic adenoviruses as
a potential new class of antitumor agents (Bischoff et al., 1996;
de Vrij et al., 2010; Toth et al., 2010), our laboratory is interested
in developing recombinant oncolytic adenoviruses that will kill
tumor cells and simultaneously target the TGF-b pathways. We
have created Ad.sTbRFc, an oncolytic adenovirus expressing
sTGFbRIIFc, a protein that can directly target TGF-b and inhibit
TGF-b signaling (Seth et al., 2006; Hu et al., 2010a). Because
human telomerase reverse transcriptase (TERT) promoter is
generally expressed at higher levels in prostate cancer (Shay
and Bacchetti, 1997), we have also developed an oncolytic ad-
enovirus, TAd.sTbRFc (Hu et al., 2010a), which is similar to
Ad.sTbRFc except that the human TERT promoter drives ad-
enoviral replication.
In this study, we have examined the effects of systemic
administrations of Ad.sTbRFc, TAd.sTbRFc, and Ad(E1-)
.sTbRFc (a nonreplicating virus expressing sTGFbRIIFc) in a
prostate cancer bone metastasis model. Our results show
that infection of prostate tumor cells with Ad(E1-).sTbRFc,
Ad.sTbRFc, and TAd.sTbRFc produced sTGFbRIIFc protein,
resulting in the inhibition of TGF-b signaling; and that
Ad.sTbRFc and TAd.sTbRFc produced high levels of viral
replication in tumor cells. We have shown that intravenous
injection of Ad.sTbRFc and TAd.sTbRFc caused inhibition of
skeletal tumor growth and tumor-induced hypercalcemia.
Ad(E1-).sTbRFc exhibited antitumor activity, albeit weaker
than that of oncolytic adenoviruses, and did not inhibit hy-
percalcemia. Our work described here suggests that Ad.sTbRFc
and TAd.sTbRFc, the two oncolytic adenoviruses targeting
TGF-b signaling, can be developed as potential drugs for the
treatment of prostate cancer bone metastases.
Materials and Methods
Cell culture
PC-3 and DU-145 (human prostate tumor cell lines), and
TRAMP-C2, a mouse prostate tumor cell line, were pur-
chased from the American Type Culture Collection (ATCC,
Manassas, VA), and the PC-3-luc cell line was produced by
transducing PC-3 cells with a retrovirus expressing luciferase
gene as previously described (Loberg et al., 2006). All pros-
tate tumor cell lines were cultured in RPMI 1640 medium
containing 10% fetal calf serum. HEK293, a human embry-
onic kidney epithelial cell line (ATCC), was maintained in
Dulbecco’s modified Eagle’s medium (DMEM) containing
10% fetal calf serum. All medium components were pur-
chased from Gibco/Invitrogen (Grand Island, NY).
Adenoviral vectors
Adenoviral vectors used in these studies were as follows:
Ad(E1-).sTbRFc, an E1– adenovirus expressing sTGFbRIIFc;
Ad.GFPluc, an adenovirus expressing the GFP–luc gene; Ad
.sTbRFc, an oncolytic adenovirus expressing the sTGFbRIIFc
gene; and TAd.sTbRFc, an oncolytic adenovirus expressing the
sTGFbRIIFC gene except that the TERT promoter drives viral
replication. Oncolytic adenoviruses were constructed with a
dl01/07 mutant of Ad5, containing two deletion mutations in the
E1A region (Howe et al., 2000) as previously described (Seth
et al., 2006; Hu et al., 2010a). Adenoviral vectors were grown in
HEK293 cells and purified by double CsCl2 gradient centrifu-
gation as described (Katayose et al., 1995). Viral particle (VP)
numbers were determined by measuring the optical density at
260 nm (OD260) of sodium dodecyl sulfate-treated purified
adenoviral solutions.
Adenoviral replication assay
Cells were plated in 6-well dishes (4 · 105 cells per well).
The next day, cells were incubated with adenoviral vectors
(2.5 · 104 VP/cell) for 3 hr. Cells were washed three times
with medium, and the incubations were continued for 48 hr.
Both 3- and 48-hr samples were used to prepare crude viral
lysates, and various aliquots were used to infect HEK293
cells. Viral plaque assays were conducted as described earlier
(Hu et al., 2010a). Viral titers were represented as viral burst
size (an increase in viral titer from 3 to 48 hr) as previously
described (Hu et al., 2010a).
Cytotoxicity assays
To examine virus-induced cytotoxicity, cells were plated
in 96-well plates (103 cells per well). The next day, cells were
infected with various doses of adenoviral vector, and the
incubations were continued for 7 days. Cells were washed,
fixed, and stained with sulforhodamine B (Sigma-Aldrich, St.
Louis, MO), and the absorbance at 564 nm (A564) was mea-
sured as previously described (Katayose et al., 1995). Un-
treated control cells were considered to have 100% survival.
sTGFbRIIFc expression
Cells were plated in 6-well dishes (4 · 105 cells per well). The
next day, cells were infected with various viral vectors (2.5 · 103
VP/cell) for 24 hr. Medium was changed to serum-free me-
dium, and the incubations were continued for another 24 hr.
Medium was collected and cell lysates were prepared and
subjected to Western blot analyses for sTGFbRIIFc expression
as previously described (Seth et al., 2006). sTGFbRIIFc levels
in the medium were examined by ELISA, using antibodies
against the human IgG Fcc fragment ( Jackson Immuno-
Research) as described (Hu et al., 2010b).
SMAD phosphorylation
Cells were plated in 6-well plates (4 · 105 cells per well). The
next day, cells were serum starved overnight. Cells were ex-
posed to TGF-b1 (1 ng/ml; Sigma-Aldrich) in the absence or
presence of sTGFbRIIFc (250 ng/ml) for 1 hr, and cell lysates
were subjected to Western blot analyses according to pub-
lished methods (Katayose et al., 1995; Hu et al., 2010a; Gupta
et al., 2011). Membranes were treated with phosphorylated
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SMAD2 (p-SMAD2), p-SMAD3, or SMAD2/3 antibodies
(Cell Signaling, Danvers, MA) followed by horseradish
peroxidase-conjugated bovine anti-rabbit IgG secondary an-
tibody (Santa Cruz Biotechnology, Santa Cruz, CA). The blots
were visualized with enhanced chemiluminescence substrate
(GE Healthcare Life Sciences, Piscataway, NJ). The p-SMAD2,
p-SMAD3, and total SMAD2/3 protein bands were quantified
with IPLab 4.0.8 imaging software (BD Biosciences, San Jose,
CA), and the ratios of p-SMADs and total SMAD2/3 were
calculated.
Animal model
All animal experiments were conducted according to an-
imal protocols approved by the Institutional Animal Care
and Use Committee of the NorthShore University Health-
System (Evanston, IL). To establish bone metastasis, PC-3-luc
cells (2.5 · 105/mouse) were injected into the left heart ven-
tricle (day 0) of 4-week-old male nude mice (NU/NU)
(Charles River Laboratories, Wilmington, MA). On day 9,
mice were subjected to bioluminescence imaging (BLI) in the
dorsal and ventral positions, using Xenogen IVIS Spectrum
imaging equipment (Caliper Life Sciences, Hopkinton, MA).
Photon signals were quantified with Living Image software
3.0 as previously described (Hu et al., 2011). Mice were dis-
tributed into various groups, with statistically indistin-
guishable BLI signals within each group. Various viral
vectors were administered via the tail vein on days 10, 13,
and 17 (2.5 · 1010 VP per injection per mouse, each injection
in a 0.1-ml volume). The control group of mice was admin-
istered buffer alone.
Bioluminescence imaging
Mice were initially imaged in the dorsal and ventral po-
sitions on day 9, and once a week until day 53, using the
Xenogen IVIS Spectrum system (Caliper Life Sciences) as
previously described (Hu et al., 2011). Mice were injected
intraperitoneally with 100 ll (150 mg/kg) of the d-luciferin
solution (Gold Biotechnology, St. Louis, MO). During image
acquisition, mice were kept under anesthesia with 1.5–2.0%
isoflurane. Signal intensity was quantified as the total flux
(photons per second) within regions of interest (ROIs) in both
left and right hind limbs, using Living Image software 3.0
(Caliper Life Sciences) as described (Hu et al., 2011).
X-ray radiography imaging
Mice were subjected to X-ray radiography in the prone
position, using a Faxitron X-ray system (Faxitron X-Ray,
Wheeling, IL). Bone lesions were quantified in the femur and
tibia of both hind limbs, using ImageJ software (National
Institutes of Health, Bethesda, MD) as described earlier (Hu
et al., 2010b, 2011).
Calcium and sTGFbRIIFc measurements in blood
At the terminal time point (day 53), mice were killed after
blood collection. Serum was obtained by centrifuging blood
at 3000 rpm for 10 min. Calcium concentrations were mea-
sured with a QuantiChrom calcium assay kit (BioAssay
Systems, Hayward, CA). sTGFbRIIFc amounts in serum
samples were determined by ELISA according to published
methods (Hu et al., 2010a).
Tumor burden analyses and osteoclast measurements
Mice were killed on day 53, and long bones were isolated
from hind limbs. Tibia and femur were fixed in formalde-
hyde, paraffin embedded, and sliced, and median sagittal
sections were subjected to hematoxylin and eosin (H&E)
staining as described (Hu et al., 2011). Slices were photo-
graphed (magnification, · 20), tumors were marked (yellow
outline), and tumor areas were calculated with NIS-Elements
BR 3.10 software (Nikon, Melville, NY). Bone slices were
stained with tartrate-resistant acid phosphatase (TRAP) as
described (Hu et al., 2011). Tumor–bone interface length was
measured, and multinucleated TRAP-positive osteoclasts
across the tumor–bone interface were counted on TRAP-
stained slices.
Synchrotron micro-computed tomography
Synchrotron micro-computed tomography (microCT),
used to image volumes of representative hind limbs of each
treatment group, was performed with station 2-BM of the
Advanced Photon Source (APS) at Argonne National La-
boratory (Argonne, IL), using the dedicated microCT in-
strument (Wang et al., 2001). The following conditions were
used for data collection: 15 keV, 0.12-degree rotation incre-
ment, 180-degree rotation range, and (2K)2 reconstructions
with 2.9-lm isotropic volume elements (voxels). Three-
dimensional (3-D) images of bone sections spanning 3.0 mm
below the growth plate regions were constructed with
Amira 5.3.2 software (Visage Imaging, San Diego, CA).
Statistical evaluations
All statistical analyses were performed with GraphPad
Prism 5 for Windows (GraphPad Software, San Diego, CA).
Data are presented as means – SEM. To analyze time course
experiments to evaluate BLI signal progression, X-ray-based
lesion size progression, and body weight progression, two-
way repeated-measure analysis of variance (ANOVA) fol-
lowed by Bonferroni post-tests was used. For multiple group
analyses for BLI signal fold inductions, X-ray-positive lesion
sizes, tumor burden, plasma calcium levels, and osteoclast
numbers, statistical significance was analyzed by one-way
ANOVA followed by Bonferroni post-tests. A chi-square test
was used to analyze tumor-free incidence data. p < 0.05 was
considered a statistically significant difference.
Results
Adenovirus-mediated transgene expression
and viral replication in prostate cancer cells
To examine whether prostate cancer cells are appropriate
targets for adenoviral vectors, PC-3, DU-145, and TRAMP-
C2 cells were infected with Ad.GFPluc for 24 hr and exam-
ined under a florescence microscope. Human prostate tumor
cell lines PC-3 and DU-145 produced green fluorescent pro-
tein (GFP) expression in nearly 100% of cells (Fig. 1A). Mouse
tumor cell line TRAMP-C2 also expressed GFP protein,
although the signal was slightly weaker. To examine
adenovirus-mediated sTGFbRIIFc expression in prostate
tumor cells, PC-3, DU-145, and TRAMP-C2 cells were
exposed to Ad(E1-).sTbRFc, Ad.sTbRFc, and TAd.sTbRFc
for 48 hr, and sTGFbRIIFc expression was examined by
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FIG. 1. Adenovirus-mediated transgene expression in prostate tumor cells. (A) PC-3, DU-145, and TRAMP-C2 cells were
infected with Ad.GFPluc (2.5 · 104 VP/cell) for 24 hr. Cells were also stained with DAPI and were photographed ( · 200),
using a florescence microscope. (B) PC-3, DU-145, and TRAMP-C2 cells were infected with various adenoviral vectors
(2.5 · 103 VP/cell) for 48 hr. Cell lysates and the media were subjected to Western blot analyses for sTGFbRIIFc expression.
(C) Extracellular media were used to measure sTGFbRIIFc levels by ELISA. Shown are the amounts of sTGFbRIIFc per
milliliter of medium. (D) TGF-b1-mediated SMAD2 and SMAD3 phosphorylation in prostate tumor cells. PC-3, DU-145, and
TRAMP-C2 cells were exposed to TGF-b1 (1 ng/ml) (Sigma-Aldrich, St. Louis, MO) for 60 min in the absence or presence of
sTGFbRIIFc (250 ng/ml). Cell lysates were examined for p-SMAD2, p-SMAD3, and total SMAD2/3 by Western blot analysis.
(E) The p-SMAD2, p-SMAD3, and total SMAD2/3 protein bands were quantified, and ratios of p-SMAD2 and total SMAD2/
3 were calculated and are shown. (F) Ratios of p-SMAD3 and total SMAD2/3.
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Western blot analysis. As shown in Fig. 1B, all three cell
lines produced sTGFbRIIFc protein, which was secreted
into the extracellular medium (Fig. 1B). The amounts of
sTGFbRIIFc in the media from Ad(E1-).sTbRFc-, Ad.sTbRFc-,
and TAd.sTbRFc-infected PC-3, DU-145, and TRAMP-C2 cells
were in the range of 0.22–8.02 lg/ml (Fig. 1C).
To examine the effect of sTGFbRIIFc on TGF-b-mediated
signaling, PC-3, DU-145, and TRAMP-C2 cells were ex-
posed to TGF-b1 for 1 hr, and cell lysates were analyzed for
the presence of phosphorylated SMAD2 (p-SMAD2) and
SMAD3 (p-SMAD3) proteins. Western blot results indi-
cated that in all three cell lines TGF-b1 induced SMAD2 and
SMAD3 phosphorylation; however, total SMAD2 and
SMAD3 levels were relatively less altered (Fig. 1D). In-
cubation of TGF-b1 with sTGFbRIIFc reduced TGF-b-
dependent SMAD2 and SMAD3 phosphorylation (Fig. 1D).
Quantification of p-SMAD2 confirmed TGF-b-mediated in-
duction of p-SMAD2 and p-SMAD3, and the inhibition of
TGF-b-dependent SMAD2 and SMAD3 phosphorylation by
sTGFbRIIFc in all three cell lines (Fig. 1E and F). Interest-
ingly, basal levels of p-SMAD3 were relatively higher in the
TRAMPC-2 tumor cell line, which could partly explain the
relatively lesser induction by TGF-b1.
Next, we examined the replication potential of oncolytic
viruses in prostate tumor cells. PC-3, DU-145, and TRAMP-
C2 cells were exposed to Ad(E1-).sTbRFc, Ad.sTbRFc, or
TAd.sTbRFc for 3 or 48 hr, and viral titers (burst sizes) were
determined. There was a large increase in viral titers, on the
order of 104 per cell, in PC-3 cells infected with Ad.sTbRFc
and TAd.sTbRFc, whereas no significant viral titers were
observed in cells infected with Ad(E1-).sTbRFc (Fig. 2A).
Similar viral titers were observed in DU-145 cells (Fig. 2A).
Mouse TRAMP-C2 cells, however, did not support replica-
tion of either Ad.sTbRFc or TAd.sTbRFc (Fig. 2A). To ex-
amine virus-induced cytotoxicity, prostate tumor cells were
exposed to the various viral vectors for 7 days and cytotox-
icity assays were conducted, using sulforhodamine assays.
Ad.sTbRFc and TAd.sTbRFc infection produced cytotoxicity
in PC-3 and DU-145 cells (Fig. 2B and C). The IC50 values of
Ad.sTbRFc and TAd.sTbRFc were about 50- to 100-fold
lower than that of the nonreplicating Ad(E1-).sTbRFc, indi-
cating that oncolytic adenovirus-induced replication resulted
in cytotoxicity in human prostate tumor cells (Fig. 2B and C).
As expected, the oncolytic adenoviruses induced minimal
cytotoxicity in mouse TRAMP-C2 cells (Fig. 2D). These re-
sults indicate that oncolytic adenoviral vectors can replicate
and induce cytotoxicity in human prostate cancer cells,
whereas mouse cells are not permissive for viral replication
and are relatively resistant to the cytotoxic effects of the
oncolytic viral vectors. However, in both the PC-3 and DU-
145 cell lines, TAd.sTbRFc was slightly weaker than
Ad.sTbRFc in producing cytotoxicity and viral replication.
Effect of intravenous injection of adenoviral vectors
on prostate cancer bone metastasis: BLI studies
Next, we examined the effect of systemic administration of
Ad(E1-).sTbRFc, Ad.sTbRFc, and TAd.sTbRFc on the pro-
gression of established prostate cancer bone metastases in a
nude mouse model. PC-3-luc cells were injected into the left
heart ventricle of male nude mice. After 9 days, mice were
subjected to BLI in the dorsal and ventral positions. Mice
were distributed into various groups with nearly equal BLI
signal in the hind limbs (in the range of 5.11–6.78 · 105
photons/sec) within each treatment group. On days 10, 13,
and 17, mice were injected with buffer or one of the various
FIG. 2. Adenoviral repli-
cation and cytotoxicity in
prostate tumor cells. (A)
PC-3, DU-145, and
TRAMP-C2 cells were in-
fected with various viral
vectors for 3 or 48 hr. Crude
viral lysates were prepared
and used to measure viral
titers in HEK293 cells. Viral
burst sizes (ratio of 48-hr to
3-hr titers) are shown.
(B) PC3, (C) DU-145, and
(D) TRAMP-C2 cells were
exposed to various doses
of viral vectors for 7 days.
The cytotoxicity assays were
conducted by sulforhoda-
mine staining. Mock-infected
cells were considered to
have 100% survival. Color
images available online at
www.liebertpub.com/hum
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adenoviral vectors (2.5 · 1010 VP per mouse per injection,
using 0.1 ml of buffer) via the tail vein. Mice were subjected
to whole-body BLI on day 16, and once per week thereafter
until day 53. Representative mice (one from each group),
imaged in the dorsal and ventral positions on days 9 and 53,
are shown in Fig. 3A. BLI signals in the hind limbs (within
the red circles indicated in Fig. 3A) were quantified and are
shown in Fig. 3B. There was a time-dependent increase in
BLI signal reaching 1.38 · 1011 photons/sec by day 53 in the
group of mice that had received buffer alone. During the
course of the experiment, there was a significant inhibition of
tumor growth in the groups of mice that had received Ad(E1-)
.sTbRFc ( p < 0.001), Ad.sTbRFc ( p < 0.001), and TAd.sTbRFc
( p < 0.001) (Fig. 3B). The fold increases in BLI signal from day
9 to day 53 were calculated for each of the treatment groups
and are shown in Fig. 3C. There was a 117,796 – 46,380-fold
increase in BLI signal from day 9 to day 53 in the buffer-
treated group. The fold increases in BLI signal from the
groups treated with Ad(E1-).sTbRFc, Ad.sTbRFc, and TAd
.sTbRFc were reduced to 13,102 – 10,070, 6493 – 5783, and
3887 – 2567, respectively, which represents significant inhi-
bitions of BLI signal fold increase in the mice treated with
Ad(E1-).sTbRFc ( p < 0.05), Ad.sTbRFc ( p < 0.05), and TAd
.sTbRFc ( p < 0.05).
Effect of intravenous injection of adenoviral vectors
on prostate cancer bone metastasis: X-ray
radiographic analyses
To further examine the effect of Ad(E1-).sTbRFc,
Ad.sTbRFc, and TAd.sTbRFc on skeletal metastases, mice
were subjected to X-ray radiography once per week, using
the Faxitron X-ray system. X-ray images of representative
mice in various treatment groups are shown in Fig. 4A;
the presence of skeletal tumors is marked by red arrows. In
the buffer-treated group osteolytic lesions began to appear
by day 16 (Fig. 4A), and the tumor sizes increased over time
until day 53 (Fig. 4A and B). There was a significant inhibi-
tion of tumor progression in groups treated with Ad(E1-).
sTbRFc ( p < 0.001), Ad.sTbRFc ( p < 0.001), and TAd.sTbRFc
( p < 0.001) (Fig. 4B). On day 53, the lesion size in the buffer-
treated group was 13.16 – 2.59 mm2 (Fig. 4C); tumor sizes in
groups treated with Ad(E1-).sTbRFc, Ad.sTbRFc, and TAd.
sTbRFc were 6.84 – 1.56, 2.22 – 1.11, and 4.76 – 1.47 mm2, re-
spectively (Fig. 4C). These results indicate that Ad(E1-).
sTbRFc treatment did not cause a significant reduction in
tumor size. However, there was significant inhibition of
tumor growth in the Ad.sTbRFc ( p < 0.001) and TAd.sTbRFc
( p < 0.05) treatment groups compared with the buffer group
FIG. 3. Effect of systemic
delivery of viral vectors on
PC-3-luc bone metastasis:
BLI analysis. PC-3-luc cells
were injected in male nude
mice (NU/NU) on day 0.
Initial BLI was performed
on day 9; mice with posi-
tive hind-limb tumors were
administered buffer or viral
vectors (via the tail vein) on
days 10, 13, and 17. BLIs
were conducted in dorsal
and ventral positions on
various days as shown. (A)
Representative mice, from
day 9 and day 53, in each
treatment group are shown.
(B) To measure bone me-
tastases, BLI signals in the
hind limbs (indicated by
red circles) were quantified
in each treatment group
(n = 9 mice per group) and
are shown. (C) BLI-fold in-
ductions from day 9 to day
53 were calculated and are
shown. p value compari-
sons with the buffer group
are shown for (B) and (C)
(*p < 0.05, ***p < 0.001).
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FIG. 4. Effect of systemic delivery of viral vectors on PC-3-luc bone metastases: X-ray radiography. Mice from the exper-
iment described in Fig. 3 were subjected to X-ray radiography on various days (n = 9 mice per group). (A) X-ray radiograph
of a representative mouse from each treatment group on days 16 and 53. Red arrows indicate the sites of osteolytic lesions.
(B) Lesion sizes in each hind-limb bones were calculated with ImageJ software. Results shown are the average lesion sizes in
the hind limbs of mice in each of the treatment groups. (C) Lesion sizes in the hind-limb bones on day 53 were calculated and
are shown. (D) Body weight of each mouse was observed on the various days shown. The average body weight for each
of the treatment groups on various days are shown. p value comparisons with buffer group are shown for (B), (C), and (D)
(*p < 0.05, ***p < 0.001). Color images available online at www.liebertpub.com/hum
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(Fig. 4C). On the basis of this we conclude that adenoviruses
expressing sTGFbRIIFc are effective in inhibiting the pro-
gression of skeletal metastases; however, oncolytic viruses
exhibited superior antitumor responses.
In addition to BLI and X-ray analyses, animal body
weights were monitored once per week. There was an in-
crease in body weight in all the treatment groups until day
44. In the buffer-treated group the mice began to lose body
weight from day 44 onward; by day 53 there was a signifi-
cant reduction in body weight in the buffer-treated group
compared with normal mice that were not inoculated with
tumor cells ( p < 0.001) (Fig. 4D). Therefore, the experiment
was terminated on day 53 and the following ex vivo analyses
of hind-limb bones and blood were conducted to further
examine the antitumor responses of the viral vectors.
Effect of intravenous injection of adenoviral vectors
on tumor burden: Histomorphometric analysis
At the end of the experiment (day 53), hind-limb bones
(from left legs) were isolated for histomorphometric analy-
ses. Bones were sectioned, and the median sagittal sections
were stained with H&E. Figure 5A shows a representative
bone sample from each of the treatment groups. In the
buffer-treated group, bone marrow was nearly replaced by
tumor cells; eight of nine bones had tumor lesions (Fig. 5A
and B). Among the adenoviral vectors, only Ad.sTbRFc
treatment resulted in a significant increase in tumor-free
bones (six of nine) ( p < 0.05). Tumor burden in the tibia and
femur was measured as described in Materials and Methods.
In the buffer-treated group, tumor size was 5.98 – 1.30 mm2
(Fig. 5C). Tumor sizes in the Ad(E1-).sTbRFc, Ad.sTbRFc,
and TAd.sTbRFc groups were 2.05 – 0.89, 1.54 – 1.05, and
2.26 – 1.04, respectively, indicating a significant reduction in
tumor burden in the Ad.sTbRFc-treated group ( p < 0.05), but
not in the TAd.sTbRFc and Ad(E1-).sTbRFc groups (Fig. 5C).
Thus, on the basis of histomorphometric analyses, Ad.sTbRFc
treatment appears to be the most effective.
Effect of intravenous injection of adenoviral vectors
on hypercalcemia, osteoclast numbers,
and synchrotron microCT of hind-limb bones
Serum samples obtained at the terminal time point (day
53) were analyzed for calcium levels as an indicator of
tumor-induced hypercalcemia. The average serum calcium
level of the buffer-treated group was 10.41 – 0.67 mg/dl,
which is significantly higher than the average calcium level
(7.38 – 0.31 mg/dl) of age-matched normal mice ( p < 0.001)
(Fig. 6A), indicating that PC-3 tumors induced hypercalce-
mia. In the Ad(E1-).sTbRFc treatment group, calcium levels
were 10.00 – 0.59 mg/dl, which is also significantly higher
than the normal level ( p < 0.01). There was, however, a de-
crease in calcium level in Ad.sTbRFc and TAd.sTbRFc
treatment groups, that is, to 8.40 – 0.20 and 8.64 – 0.31 mg/dl,
respectively, showing no significant differences in cal-
cium level compared with the normal level. However, only
Ad.sTbRFc treatment resulted in a significant reduction in
calcium level compared with the buffer group ( p < 0.05)
(Fig. 6A). To confirm vector-induced sTGFbRIIFc production,
FIG. 5. Analysis of tumor
burden by histomorphometric
analyses. On day 53, bones
from hind limbs were isolated,
and midsagittal bone sections
were subjected to H&E stain-
ing. Samples (n = 9) were vi-
sualized under the microscope
and photographed (original
magnification, · 20). Tumor
outlines are marked with yel-
low lines. (A) Shown are ex-
amples of H&E-stained bone
samples from each treatment
group. (B) Number of bones
without any visible tumor
in each treatment group. (C)
Tumor areas were measured
within the yellow outlines. p
value comparisons with buffer
group are shown for (B) and
(C) (*p < 0.05).
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blood levels were analyzed by ELISA. Blood samples de-
rived from the buffer group had low levels (3.96 – 1.05 ng/
ml) of sTGFbRIIFc protein (Fig. 6B). Mice treated with
Ad(E1-).sTbRFc, Ad.sTbRFc, and TAd.sTbRFc viruses pro-
duced, respectively, 1.89 – 1.05, 84.17 – 14.53, and 152.70 –
54.20 mg of sTGFbRIIFc per milliliter in the blood (Fig. 6B).
Taken together, these results indicate that a combination of
viral replication and sTGFbRIIFc production is effective in
inhibiting prostate tumor cell-induced hypercalcemia.
Because osteoclast cells are responsible for causing bone
resorption associated with osteolytic bone destruction, bone
samples from various treatment groups were analyzed for
FIG. 6. Serum calcium,
sTGFbRIIFc levels, and oste-
oclast numbers at tumor–bone
interface and synchrotron
microCT analyses. (A) Serum
samples collected on day 53
were used to measure cal-
cium levels (n = 9 mice per
group). (B) Serum samples
were also examined for
sTGFbRIIFc levels by ELISA
(n = 9 mice per group). (C)
Bone samples (n = 9 per
group) were stained for
TRAP multinucleated osteo-
clasts. Red arrows point to a




(yellow line was drawn to
measure tumor–bone inter-
face) were determined and
are shown. (n = 9 per group).
(E) Bones from various treat-
ment groups (n = 3 per group)
were collected on day 53 and
were analyzed by synchro-
tron microCT. Shown is a
representative example of 3-
D reconstructions of bones
from normal mice and mice
from various treatment
groups. Arrows indicate the
sites of osteolytic bone de-
struction (top). Individual
microCT slices around the
growth plate (middle) and
1.45 mm downstream of the
growth plate (bottom) of tibia
bone. Arrows indicate the sites
of tumor-induced trabecular
and cortical bone destruction.
p value comparisons with the
normal group are shown for
(A) (**p < 0.01, ***p < 0.001). p
value comparisons with buffer
group are shown for (A) and
(D) (*p < 0.05).
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the presence of osteoclasts. Multinucleated tartrate-resistant
acid phosphatase (TRAP)-positive osteoclasts were observed
across the tumor–bone interface in the buffer-treated group
(Fig. 6C). The osteoclast numbers per millimeter of tumor–
bone interface were measured in each bone and are shown in
Fig. 6D. The buffer treatment group had 5.14 – 1.16 osteo-
clasts per millimeter. The osteoclast numbers in the Ad
(E1-).sTbRFc, Ad.sTbRFc, and TAd.sTbRFc treatment groups
were reduced to 1.75 – 0.62, 1.37 – 0.72, and 4.35 – 1.04 per
millimeter, respectively. Among the three viral vectors, only
Ad.sTbRFc treatment resulted in a significant inhibition
of osteoclast numbers compared with the buffer group
( p < 0.05). These results therefore indicate that Ad.sTbRFc
was effective in reducing total osteoclast numbers across
the tumor–bone interface.
Tumor-induced bone destruction in hind-limb bones was
further examined by synchrotron microCT. This can provide
spatial resolution and contrast sensitivity that is superior to
that in radiography and X-ray tube-based microCT (Stock,
2008). Areas about 3.0 mm below the growth plate were
scanned and used to reconstruct 3-D images, using Amira
software. Figure 6E (top) shows the 3-D reconstructions of
a representative bone from each treatment group. The tibia
derived from the buffer-treated group has large osteolytic
lesions in the metaphysis region. In the Ad(E1-).sTbRFc
treatment group, the osteolytic lesions were still apparent.
Bones derived from mice in the Ad.sTbRFc and TAd.sTbRFc
treatment groups appeared relatively normal (Fig. 6E, top).
To further examine the nature of bone destruction, skeletal
sections near the growth plate (Fig. 6E, middle) and 1.45 mm
below the growth plate (Fig. 6E, bottom) were examined.
Bones in the buffer- and Ad(E1-).sTbRFc-treated groups
demonstrated clear trabecular and cortical destruction
(Fig. 6E, top and middle); bones from the Ad.sTbRFc and
TAd.sTbRFc groups appeared to have the least trabecular
and cortical bone destruction. The sample numbers, how-
ever, were too few for detailed statistical analyses of various
bone parameters.
Discussion
The main finding in this paper is that intravenous delivery of
Ad.sTbRFc, an oncolytic adenovirus expressing sTGFbRIIFc in
an animal model of prostate cancer bone metastasis, is effective
in treating the established bone metastases, inhibiting hyper-
calcemia, and resulting in tumor-free mice. Another oncolytic
virus, TAd.sTbRFc, expressing sTGFbRIIFc, is also effective in
inhibiting bone metastases, and no significant differences were
observed between Ad.sTbRFc and TAd.sTbRFc in multiple
assays including tumor growth inhibition by BLI analyses, fold
induction of BLI increase, tumor growth progression or lesion
area on day 53 by X-ray analyses, body weight analyses, tumor
burden analyses, serum calcium levels, and TRAP-positive
osteoclast numbers. However, TAd.sTbRFc did not produce
significant tumor-free incidence. This is not surprising consid-
ering that the hTERT promoter, although tumor specific, is
weaker than viral promoters such as the E1A promoter (Hu
et al., 2010a). Ad(E1-).sTbRFc, a nonreplicating virus expressing
sTGFbRIIFc, was effective in inhibiting bone metastases but
weaker than Ad.sTbRFc; it did not result in significant tumor-
free incidence and failed to inhibit hypercalcemia. These results
suggest that the combination of viral replication and
sTGFbRIIFc expression is critical for the desired antitumor re-
sponses in this prostate cancer bone metastasis model.
Our studies described here suggest that human prostate
cancer cells are excellent targets for adenovirus-mediated
cancer therapy. We have shown that prostate cancer cells
support adenoviral replication and simultaneously produce
high levels of transgene expression. It is noteworthy that
an important study conducted in McCormick’s laboratory
showed that expression of the coxsackie–adenovirus receptor
(CAR), the primary adenoviral receptor, correlated with the
Gleason score of prostate tumors; CAR was highly expressed
in tumor specimens derived from prostate cancer patients
with metastases (Rauen et al., 2002). Therefore, it is not sur-
prising that adenoviral vectors are effective vectors for tar-
geting the metastatic prostate cancer cellular models
described here. In fact, in clinical trials conducted in patients
with prostate cancer, adenoviruses have been found to be
generally safe and have shown some antitumor efficacy
(Kubo et al., 2003; Shirakawa et al., 2007; de Vrij et al., 2010;
Adamson et al., 2012).
On the basis of the studies described here, we postulate the
following mechanism by which overexpression of sTGFbRIIFc,
coupled with viral replication, could inhibit prostate cancer
bone metastases, osteoclast activation, and bone resorption.
Systemic delivery of Ad.sTbRFc vector would result in its up-
take in skeletal tumors, where it will replicate and cause some
oncolysis. sTGFbRIIFc, the result of adenovirus-mediated
production in the tumors, will be released into the tumor mi-
croenvironment, where it will bind with TGF-b, inhibit TGF-b-
dependent SMAD2 and SMAD3 phosphorylation, and inhibit
other downstream signals in tumor cells and in other cells
present in the microenvironment. This will inhibit prometa-
static signaling pathways prevalent in the tumor cells, inhibit
osteoclastogenesis, and induce osteoblast differentiation. Be-
cause bone resorption results in hypercalcemia, as well as the
release of several tumor-promoting growth factors such as
insulin-like growth factor-1, inhibition of bone resorption will
thus inhibit hypercalcemia and reduce the release of various
growth factors from bone, resulting in further inhibition of
tumor growth. As observed here, this coupled with concurrent
viral replication leading to tumor cell death will result in severe
inhibition of bone metastases. Although some of these steps
have been examined in the current study, understanding the
details of the mechanisms outlined here would be an important
area of future research.
Although a great percentage of prostate cancer skeletal
metastases are osteoblastic in nature, there is also an un-
derlying osteolytic component (Schneider et al., 2005; Sato
et al., 2008; Jin et al., 2011; Lee et al., 2011; Sturge et al., 2011).
In fact, the drugs bisphosphonates and denosumab, devel-
oped for treating human prostate cancer bone metastases, as
described here for Ad.sTbRFc, also target the osteolytic
component. Bisphosphonates target osteoclasts and can in-
hibit bone resorption; denosumab is a monoclonal antibody
against RANKL and can therefore inhibit RANKL-depen-
dent osteoclastogenesis (Coleman, 2011; Fizazi et al., 2011;
Smith et al., 2011). Interestingly, TGF-b1 has been shown to
directly induce RANKL expression in a mouse prostate
cancer model that predominantly produces osteoblastic le-
sions (Zhang et al., 2004). It is therefore possible that in-
hibiting TGF-b activity could result in the inhibition of
osteoclast function even in prostate cancers that produce
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mixed osteoblastic and osteolytic lesions. One potential ad-
vantage of using oncolytic adenovirus such as Ad.sTbRFc to
treat established prostate cancer metastases is that in addi-
tion to inhibiting bone resorption, Ad.sTbRFc is also directly
cytotoxic, which can potentially contribute toward signifi-
cant tumor-free incidence, a desired clinical outcome of
cancer therapy.
In summary, our work presented here suggests that on-
colytic viruses expressing sTGFbRIIFc can be potentially
developed for the treatment of skeletal metastases second-
ary to prostate cancer. Clearly, additional efficacy, safety,
and toxicity studies in animal models would be needed
before initiating any clinical trials in patients with prostate
cancer. In particular, two in vivo barriers of systemic de-
livery of oncolytic adenoviruses that need to be addressed
are as follows: liver tropism of the adenoviruses and the
immune response to adenoviral vectors, both of which limit
the use of this approach. To reduce liver sequestration of
Ad5-based viruses, we have begun creating Ad5/48 chi-
meric hexon-containing, liver-detargeted oncolytic adeno-
viruses, in which seven hypervariable regions of Ad48
hexon are inserted in the Ad5 backbone (Zhang et al., 2011);
such liver-detargeted chimeric oncolytic viruses can also
be developed to target prostate cancers. Regarding the im-
mune response issue, a large body of research has been
done to develop ways to inhibit and/or evade the immune
responses to adenoviruses, for example, the use of serotype
switching, use of immune-suppressive agents, chemical
modifications of adenoviral capsids, microencapsulation of
the adenovirus, or the use of other viral and nonviral vec-
tors (Lamfers et al., 2006; Liu and Kirn, 2008; Morille et al.,
2008; Seow and Wood, 2009; Stanford et al., 2010; Ahi et al.,
2011). Considering the urgent need to develop novel ther-
apies of bone metastases of prostate cancer, we will direct
our future effort to obtain such data.
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